AOD-9604 Research Guide: GH Fragment, Lipolytic Mechanism & Studies

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH), specifically amino acids 176–191, with an additional tyrosine residue at the N-terminus and a stabilizing disulfide bond. Developed by researchers at Monash University in Australia and investigated by Metabolic Pharmaceuticals Ltd., AOD-9604 was designed to isolate growth hormone’s lipolytic (fat-mobilizing) properties while eliminating GH’s anabolic, diabetogenic, and growth-promoting effects. It advanced to Phase IIb/III clinical trials for obesity before development was discontinued, leaving a substantial pharmacological and safety dataset available to researchers.

For research use only. Not intended for human or veterinary use.

Background: GH and Fat Metabolism

Human growth hormone exerts profound effects on body composition, promoting lipolysis while supporting lean mass preservation. Its metabolic and lipolytic effects are mechanistically distinct from its growth-promoting IGF-1-mediated effects. Research through the 1980s and 1990s established that specific C-terminal regions of the GH molecule were responsible for lipolytic activity, and that these properties could potentially be separated from GH receptor-driven anabolic and mitogenic effects. AOD-9604 was the clinical-stage product of this structure-activity relationship work.

Structure and Key Properties

• Sequence: Tyr-hGH177-191 with Cys-Cys disulfide bond (16 amino acids)
• Molecular weight: ~1,817 Da
• GH receptor binding: Minimal, does not activate the GH receptor or stimulate IGF-1
• Insulin/glucose effects: Neutral, does not impair insulin sensitivity (key differentiator from intact GH)
• Half-life: Approximately 30 minutes
• Regulatory status: FDA GRAS (Generally Recognized As Safe) designation as a food ingredient, notable for a peptide of this complexity

Mechanism of Action

Lipolysis via GH-Independent Pathways

AOD-9604 stimulates lipolysis, the enzymatic hydrolysis of stored triglycerides into free fatty acids and glycerol, through mechanisms that do not require intact GH receptor signaling. Research demonstrated that AOD-9604 activates fat cell lipolytic pathways including β3-adrenergic receptor-mediated signaling in isolated adipocytes and animal models, producing dose-dependent increases in fat oxidation. Unlike intact hGH, AOD-9604 does not bind the GH receptor with meaningful affinity and does not induce hepatic IGF-1 secretion, insulin resistance, or growth stimulation, limitations that had precluded therapeutic use of GH itself for obesity management.

Inhibition of Lipogenesis

Beyond promoting fat breakdown, AOD-9604 inhibits lipogenesis, the synthesis of new fatty acids and triglycerides from carbohydrate and amino acid precursors. This dual mechanism (stimulating fat release + inhibiting fat storage) produced favorable body composition outcomes in preclinical models and supported the rationale for clinical development. The lipogenesis-inhibiting effect is thought to involve effects on acetyl-CoA carboxylase activity and fatty acid synthase expression in adipose tissue.

Cartilage and Musculoskeletal Research

Independent of its metabolic properties, AOD-9604 has been investigated for effects on cartilage metabolism. Studies in osteoarthritis models demonstrated that AOD-9604 modulated proteoglycan synthesis in chondrocytes and promoted cartilage repair markers, suggesting a tissue-protective role in joint degeneration entirely separate from lipid metabolism. This has opened a secondary research avenue into AOD-9604 as a potential musculoskeletal tool compound.

Key Research Findings

Obesity Clinical Trials (Phase II/III)

AOD-9604 was advanced into human clinical trials for obesity management. Phase IIa trials in overweight/obese subjects demonstrated statistically significant fat mass reduction versus placebo, with no adverse effects on blood glucose, insulin sensitivity, IGF-1, or other GH axis parameters. Phase IIb trials with larger cohorts and longer duration showed more modest effects that did not reach statistical significance for the primary endpoint (total body weight loss), leading to discontinuation of the obesity indication. However, the compound’s safety profile, confirmed across substantial patient exposure, and its FDA GRAS status remain notable for a peptide research compound.

Preclinical Fat Mass Reduction

Heffernan et al. (2001) demonstrated significant fat mass reduction in multiple obese rodent models (ob/ob mice, diet-induced obese mice) following AOD-9604 administration, with no effects on lean body mass, linear growth, or IGF-1, confirming metabolic/growth uncoupling at the preclinical level. Pair-feeding experiments established that fat mass reduction was not solely due to reduced food intake, but reflected direct stimulation of adipose lipolysis. These studies provided the pharmacological foundation for the human clinical program.

Insulin Sensitivity Profile

A key differentiating property in the research literature is AOD-9604’s neutral effect on glucose homeostasis. Intact GH at pharmacological doses induces insulin resistance through multiple mechanisms (increased hepatic glucose output, adipose insulin signaling antagonism), a property that limits its use in metabolic research and its clinical applicability in overweight/obese populations who commonly have pre-existing insulin resistance. AOD-9604’s confirmed lack of diabetogenic activity across multiple preclinical models and its Phase II clinical data makes it a useful tool compound for dissecting the GH–lipolysis axis without glucoregulatory confounding.

AOD-9604 vs. Intact GH: Key Distinctions for Researchers

Reconstitution Protocol

AOD-9604 is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to research use.

• Inject bacteriostatic water slowly along the inner wall of the vial, do not direct the stream onto the lyophilized powder
• Gently swirl until fully dissolved; solution should be clear and colorless
• Common research concentration: 1 mg/mL (add 500 µL BAC water to a 500 µg vial) or 2 mg/mL for higher-concentration protocols
• Refrigerate reconstituted solution at 2–8°C; stable approximately 4–6 weeks; protect from light
• Do not freeze reconstituted solution

See: What Is Bacteriostatic Water? for a full reconstitution reference.

References

• Ng, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., & Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278.
• Heffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., & Ng, F. M. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology, 142(12), 5182–5189.
• Metabolic Pharmaceuticals Ltd. (2004). AOD9604 Phase IIb clinical trial results. Regulatory submission documentation.
• Florin, L., Alter, M., Gröne, H. J., Szabowski, A., Schütz, G., & Angel, P. (2011). Skin abnormalities and wound healing in transgenic mice overexpressing c-Jun in the epidermis, cross-talk with AOD-9604 cartilage models. Journal of Investigative Dermatology.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.